Methotrexate has no antifibrotic effect in bleomycin-induced experimental scleroderma

Journal of Rheumatology

Volumn 37, Issue 3, 2010, Pages 678-679

  Ozgen, Metin ^a   Koca, Suleyman S ^a   Isik, Ahmet ^a   Ozercan, Ibrahim H ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; HYDROXYPROLINE; INTERLEUKIN 2; INTERLEUKIN 4; METHOTREXATE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; EOSINOPHIL; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; LETTER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCLERODERMA; SKINFOLD THICKNESS; SUBCUTANEOUS TISSUE;

ANIMALS; ANTIRHEUMATIC AGENTS; BLEOMYCIN; DISEASE MODELS, ANIMAL; FIBROSIS; INJECTIONS, INTRAPERITONEAL; METHOTREXATE; MICE; MICE, INBRED BALB C; SCLERODERMA, SYSTEMIC; SKIN; TREATMENT OUTCOME;

EID: 77949754964     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090961     Document Type: Letter

References (10)

1. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-72.
2. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
3. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999;112:456-62.
4. Yamamoto T, Takagawa S, Katayama I, Nishioka K. Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol 1999;92:6-13.
5. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4- carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986;236:193-200.
6. Chan ES, Fernandez P, Merchant AA, Montesinos MC, Trzaska S, Desai A, et al. Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum 2006;54:2632-42.
7. van den Hoogen FH, van der Kraan PM, Boerbooms AM, van den Berg WB, van Lier HJ, van de Putte LB. Effects of methotrexate on glycosaminoglycan production by scleroderma fibroblasts in culture. Ann Rheum Dis 1993;52:758-61.
8. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004;4:583-94.
9. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67-72.
10. Herman S, Zurgil N, Langevitz P, Ehrenfeld M, Deutsch M. Methotrexate selectively modulates TH1/TH2 balance in active rheumatoid arthritis patients. Clin Exp Rheumatol 2008;26:317-23.